If you are someone who can spare a few bucks to support research into prostate cancer (and particularly the more aggressive forms of prostate cancer), please read on … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: donate, PCF, research | Leave a comment »
A recent report in the CDC’s Morbidity and Mortality Weekly Report (MMWR) may offer one of the best analyses of an increasing risk for diagnosis with and death from advanced forms of prostate cancer over the period from 2003 to 2017 (the last year for which we have accurate data from the SEER database). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: CDC, Diagnosis, epidemiology, incidence, mortality, risk | 3 Comments »
Nearly 3 years ago now, we first mentioned a surgical technique known as “Retzius-sparing” radical prostatectomy on this web site. … READ MORE …
Filed under: Management, Treatment, Uncategorized | Tagged: hood, prostatectomy, radical, Retzius-sparing, surgery, technique | 1 Comment »
The following article was written by two of the founders of Active Surveillance Patients International (ASPI) under the title “Al Roker’s forecast: rising PSA and a radical prostatectomy” and distributed largely by e-mail. It is re-posted here with the permission of the authors. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: active, celebrity, Roker, surveillance | 4 Comments »
So our good friend Howard Wolinsky has just written up his assessment on the evolution of the use of the PSA test in “screening” for prostate cancer in an article on the MedPage Today web site. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: PSA, risk, screening, test | 17 Comments »
Perhaps unsurprisingly, your sitemaster was a little distracted on March 9 this year (by both the start of the COVID-19 chaos and by his birthday) and so he utterly missed what appears to be a rather important paper on the use of 5α-reductase inhibitors (5-ARIs) in men on active surveillance (AS) for management of low-risk forms of prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 5-ARI, active, AS, Prevention, progression, surveillance | 2 Comments »
According to a media release issued on Tuesday this week by miR Scientific, the US Food and Drug Administration (FDA) has issued a Breakthrough Device Designation for the company’s new urine-based test for risk of prostate cancer (the miR Sentinel™ Prostate Test). … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: miR Sentinel, risk, test, urine | 2 Comments »
A new type of “educational” service has been brought to our attention that uses virtual reality (VR) systems allowing a number of opportunities for men to “talk” to a virtual prostate cancer patient about their own risks for prostate cancer and things like the risks and benefits of PSA testing. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: knowledge, patient, risk, testing, Treatment, virtual | 3 Comments »
The following article was originally published in the ASCO Connection magazine on September 22, 2020 (click here for the original). It was written by Anne Katz, PhD, RN, FAAN, a certified sexuality counselor at CancerCare Manitoba and nurse counselor at the Manitoba Prostate Centre. … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: distress, genital, penile, shrinkage | 5 Comments »
At the end of this month, on Tuesday, September 29, at 8:00-9:30 p.m. Eastern time (to be precise), there will be a second webinar in the series on the role of active surveillance in the management of favorable-risk forms of localized prostate cancer, coordinated by our good friend Howard Wolinsky and others. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, genetics, genomics, Helfand, surveillance, webinar | 3 Comments »
In 2013, Zumsteg et al. proposed a refinement in the NCCN “intermediate risk” classification into two subcategories, “favorable intermediate-risk (FIR)” and “unfavorable intermediate-risk (UIR).” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: adjuvant, ADT, favorable, intermediate, radiation, risk, unfavorable | 3 Comments »
